FCCC LOGO Faculty Publications
Moore KN , Martin LP , O'Malley DM , Matulonis UA , Konner JA , Vergote I , Ponte JF , Birrer MJ
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer
Future Oncol. 2018 Jan;14(2) :123-136
Back to previous list
Abstract
Resistance to platinum-based therapy poses a significant clinical challenge for the management of advanced ovarian cancer, a leading cause of cancer mortality among women. Mirvetuximab soravtansine is a novel antibody-drug conjugate that targets folate receptor-alpha, a validated molecular target for therapeutic intervention in this disease. Here, we examine mirvetuximab soravtansine's mechanism of action and pharmacology, and review its clinical evaluation in ovarian cancer to date. We focus on the favorable tolerability and encouraging signals of efficacy that have emerged, most notably in patients with platinum-resistant disease. Ongoing Phase III monotherapy and Phase Ib/II combination trials evaluating its activity in the setting of platinum resistance are emphasized, which will help define its role in the evolving landscape of ovarian cancer therapy.
Notes
1744-8301 Moore, Kathleen N Martin, Lainie P O'Malley, David M Matulonis, Ursula A Konner, Jason A Vergote, Ignace Ponte, Jose F Birrer, Michael J Review England Future Oncol. 2017 Nov 3. doi: 10.2217/fon-2017-0379.